guided patient access
Faster,Coordinated
Patient Access
Providing faster, coordinated access to innovative treatments for patients with unmet medical needs. We navigate all early access pathways to connect patients with life-changing therapies before or immediately after marketing authorisation.
Early & Fast Access
Belgium's new Early & Fast Access programs enable faster patient access to innovative medicines while generating real-world safety and efficacy data.
-
Overseen by CAT/CAIT authorities
-
Generating real-world evidence
-
Structured, controlled access
new in 2026
How We Serve Our Customers
We facilitate a range of early access mechanisms tailored to bring innovation earlier to patients in Belgium.
Comprehensive Access Solutions
Facilitating access for individual patients and physicians to medicines that are approved in other countries but not yet available in Belgium. We handle all regulatory submissions and coordination with authorities.
01
Named Patient Program
02
Compassionate Use & Medical Need
We specialise in designing and implementing compassionate use and medical need programs, compliant with the requirements of the regulatory authorities. This allows rapid and controlled access to innovative therapies prior to reimbursement.
03
Early & Fast Access Program
We are fully engaged with the Early & Fast Access programs, overseen by the CATT/CAIT, to bring transformative treatments faster to patients in need — while generating real-world medical and safety data.
why it matters
Innovation in medicines
does not stop with approval
Early access programmes enable innovative treatments to reach patients earlier in case of clear medical need. We bridge the gap between approval and reimbursement — bringing therapies to the patients who need them most, while generating the real-world evidence that supports sustainable access.